FROM RESISTANCE TO REMISSION : CLINICAL OUTCOMES OF NUTRACEUTICAL THERAPY IN PYELONEPHRITIS

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

Presented the abstract " "
(Abstract co-author(s): )

Back

E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.

E-Poster Format Requirements

PDF file
Layout: Portrait (vertical orientation)
One page only (Dim A4: 210 x 297mm or PPT)
E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
File Size: Maximum file size is 2 Megabytes (2 MB)
No hyperlinks, animated images, animations, and slide transitions
Language: English
Include your abstract number
E-posters can include QR codes, tables and photos

E-Poster

https://storage.unitedwebnetwork.com/files/1099/202af2f7d11c2f8a8365967c67a92fcf.pdf

Abstract Title *

FROM RESISTANCE TO REMISSION : CLINICAL OUTCOMES OF NUTRACEUTICAL THERAPY IN PYELONEPHRITIS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

The title will not be accepted if it exceeds 25 words.
Type in CAPITAL LETTERS.
Lowercase may be used for abbreviations only, for example, mRNA.

Co-author 1

Tahir Shaikh tahirshaikh031@gmail.com Greenwage Health Care Allied Health Sangamner India *

Co-author 2

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Introduction

Pyelonephritis in chronic kidney disease (CKD) patients is increasingly complicated by multidrug-resistant (MDR) Escherichia coli infections. These infections often resist standard allopathic treatments, necessitating exploration of integrative, non-antibiotic options. Nutraceuticals have emerged as promising adjuncts due to their antimicrobial and anti-adhesive properties.

Methods

Blood tests were conducted for ESR levels in hundred CKD patients. Those with ESR >60 mm/hr (n=100) underwent urine culture evaluation. Among these, 80% had diabetes mellitus, and sixty patients were diagnosed with pyelonephritis cause by drug-resistant E. coli. These patients received a daily regimen of nutraceutical therapy comprising Cranberry extract (500 mg) and D-Mannose (200 mg) capsules for 3 months. Clinical symptoms and microbial eradication were assessed through repeat cultures and symptom scoring at baseline and post-treatment.

Results

Fourty out of sixty patients treated with the nutraceutical regimen achieved complete symptomatic and microbiological remission. Urine cultures after three months revealed full eradication of E. coli. Improvements were noted in dysuria, fever, flank pain, and overall inflammatory markers. No recurrence occurred during the follow-up period, and no adverse effects were reported.

Conclusion

This clinical study demonstrates the effectiveness of Cranberry and D-Mannose in treating pyelonephritis among CKD patients. Nutraceutical therapy led to complete remission within three months and may offer a safe, affordable, and resistance-free alternative or adjunct to conventional antibiotics. Further large-scale, randomized trials are recommended to validate these findings and explore broader applications in nephrology practice.

Kewords